Research Paper Volume 16, Issue 6 pp 5149—5162
A novel immune-related lncRNA signature predicts the prognosis and immune landscape in ccRCC
Figure 7. The relationship between the risk assessment model and common targeted drugs, including axitinib (A), bosutinib (B), imatinib (C), pazopanib (D), rapamycin (E), sorafenib (F), sunitinib (G), temsirolimus (H).